{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:22:28Z","timestamp":1787653348093,"version":"build-2736575974"},"reference-count":50,"publisher":"Informa UK Limited","issue":"19","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2026,8,9]]},"DOI":"10.1080\/14796694.2026.2707796","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T08:02:15Z","timestamp":1785312135000},"page":"2287-2298","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Matching-adjusted indirect comparison of enzalutamide versus apalutamide with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer"],"prefix":"10.1080","volume":"22","author":[{"given":"Arun A.","family":"Azad","sequence":"first","affiliation":[{"name":"Peter MacCallum Cancer Centre","place":["Melbourne, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavik J.","family":"Pandya","sequence":"additional","affiliation":[{"name":"Medical Affairs, Astellas Pharma Global Inc., Northbrook, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant Singh","family":"Bhadauria","sequence":"additional","affiliation":[{"name":"Medical Affairs, Astellas Pharma Global Inc., Northbrook, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erhan","family":"Berrak","sequence":"additional","affiliation":[{"name":"Medical Affairs, Astellas Pharma Global Inc., Northbrook, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vagia","family":"Daki","sequence":"additional","affiliation":[{"name":"EMEA Real World Methods and Evidence Generation","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Martins","sequence":"additional","affiliation":[{"name":"EMEA Real World Methods and Evidence Generation","place":["Lisbon, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Kim","sequence":"additional","affiliation":[{"name":"Medical Affairs, Astellas Pharma Global Inc., Northbrook, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Serikoff","sequence":"additional","affiliation":[{"name":"Medical Affairs, Astellas Pharma Global Inc., Northbrook, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Baio","sequence":"additional","affiliation":[{"name":"University College London","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute","place":["Durham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"e_1_3_8_3_1","unstructured":"Referenced with permission from the NCCN clinical practice guidelines in Oncology (NCCN guidelines\u00ae) for prostate cancer. V.5.2026. \u00a9 National Comprehensive Cancer Network Inc; 2026 [cited 2026 Mar 27]. To view the most recent and complete version of the guideline go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content use or application and disclaims any responsibility for their application or use in any way."},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003452"},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00799"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00193"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.5005"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.12.021"},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903307"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03488"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-1683(24)01276-X"},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X17725740"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2526324"},{"key":"e_1_3_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-018-0106-6"},{"key":"e_1_3_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01156-5"},{"key":"e_1_3_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100510"},{"key":"e_1_3_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.05.004"},{"key":"e_1_3_8_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001568"},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2024.06.006"},{"key":"e_1_3_8_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0309941"},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01535"},{"key":"e_1_3_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115513"},{"key":"e_1_3_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00230-9"},{"key":"e_1_3_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23645"},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz396"},{"key":"e_1_3_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30082-8"},{"key":"e_1_3_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102140"},{"key":"e_1_3_8_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-022-00607-5"},{"key":"e_1_3_8_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.1970"},{"key":"e_1_3_8_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00238"},{"key":"e_1_3_8_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-023-00710-1"},{"key":"e_1_3_8_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-023-00665-3"},{"key":"e_1_3_8_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-021-03816-0"},{"key":"e_1_3_8_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyab057"},{"key":"e_1_3_8_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.3113"},{"key":"e_1_3_8_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-018-0588-8"},{"key":"e_1_3_8_37_1","unstructured":"Latimer N. NICE DSU Technical Support Document 14: Undertaking survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data 2011. 2011 [cited 2025 Oct 20]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK395885\/pdf\/Bookshelf_NBK395885.pdf"},{"key":"e_1_3_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0895-4356(97)00049-8"},{"key":"e_1_3_8_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/03610929108830654"},{"key":"e_1_3_8_40_1","unstructured":"Latimer NR Abrams KR. NICE DSU Technical Support Document 16: Adjusting survival time estimates in the presence of treatment switching. NICE Decision Support Unit Technical Support Documents. London; 2014 [cited 2025 Mar 13]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK310374\/pdf\/Bookshelf_NBK310374.pdf"},{"key":"e_1_3_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2019.103339"},{"key":"e_1_3_8_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-022-01692-9"},{"key":"e_1_3_8_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4487"},{"key":"e_1_3_8_44_1","unstructured":"European Medicines Agency (EMA). Committee for Medicinal Products for Human Use (CHMP). Assessment Report: Apalutamide (Erleada). Amsterdam: European Medicines Agency; 2019 [cited 2026 Feb 11]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/erleada-h-c-4452-ii-0001-epar-assessment-report-variation_en.pdf-0"},{"key":"e_1_3_8_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00272-w"},{"key":"e_1_3_8_46_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18121966"},{"key":"e_1_3_8_47_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2026.2695214"},{"key":"e_1_3_8_48_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200920"},{"key":"e_1_3_8_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03207-6"},{"key":"e_1_3_8_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03434-x"},{"key":"e_1_3_8_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903835"},{"key":"e_1_3_8_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70464"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2026.2707796","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14796694.2026.2707796","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2026.2707796","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T09:51:47Z","timestamp":1787651507000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2026.2707796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":50,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,8,9]]}},"alternative-id":["10.1080\/14796694.2026.2707796"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2026.2707796","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-03-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}